Sunil G. Iyer

Sunil G. Iyer

Hematology | Oncology

161 Fort Washington Avenue
New York, NY 10032

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysis.

Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysis.

Journal: Frontiers in oncology

Published: June 08, 2026

Treatment-emergent coagulopathy during azacitidine/venetoclax induction in AML.

Treatment-emergent coagulopathy during azacitidine/venetoclax induction in AML.

Journal: Blood neoplasia

Published: October 07, 2025

Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia.

Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia.

Journal: Melanoma research

Published: February 04, 2025

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.

Journal: Blood advances

Published: December 24, 2024

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms.

Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms.

Journal: Blood neoplasia

Published: December 19, 2024

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.

Journal: Bone marrow transplantation

Published: July 23, 2024

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.

Journal: Bone marrow transplantation

Published: July 23, 2024

Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.

Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.

Journal: Blood advances

Published: February 06, 2024

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia.

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia.

Journal: Blood neoplasia

Published: November 13, 2023

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia.

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia.

Journal: medRxiv : the preprint server for health sciences

Published: August 14, 2023

The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions.

The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions.

Journal: Frontiers in oncology

Published: October 06, 2022

Prevalence and Outcomes of COVID-19 among Hematology/Oncology Patients and Providers of a Community-Facing Health System during the B1.1.529 ("Omicron") SARS-CoV-2 Variant Wave.

Prevalence and Outcomes of COVID-19 among Hematology/Oncology Patients and Providers of a Community-Facing Health System during the B1.1.529 ("Omicron") SARS-CoV-2 Variant Wave.

Journal: Cancers

Published: August 29, 2022

Showing 1-12 of 26

Last Updated: 09/26/2026